Navigation Links
Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Date:8/11/2008

CALGARY, Aug. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed patient enrolment in the dose escalation portion of its U.K. clinical trial to evaluate the anti-tumour effects of systemic administration of REOLYSIN(R) in combination with docetaxel (Taxotere(R)) in patients with advanced cancers including bladder, prostate, lung and upper gastro-intestinal. The principal investigator is Professor Hardev Pandha of the Royal Surrey Hospital, U.K.

The trial (REO 010) has two components. The first is an open-label, dose-escalating, non-randomized study of REOLYSIN(R) given intravenously with docetaxel every three weeks. Standard dosages of docetaxel were delivered to patients with escalating dosages of REOLYSIN(R) intravenously. The second component of the trial includes the enrolment of a further nine patients at the top dose of REOLYSIN(R) in combination with a standard dosage of docetaxel.

"We have completed the dose escalation stage of the study," said Prof. Pandha. "Patients enrolled had previously undergone significant treatment with combination chemotherapy. The combination of REOLYSIN(R) and taxotere was safe, well tolerated with no obvious toxicity related specifically to REOLYSIN(R). Efficacy of the combination was encouraging: both objective anti-tumour responses and disease stabilization were observed radiologically."

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including bladder, lung, prostate or upper gastro-intestinal cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN(R) when administered in combination with docetaxel. Secondary objectives include the evaluation of immune resp
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 The Fertility Centers of ... Dr. Danielle Vitiello has taken on a new and ... Vitiello will provide guidance, leadership, oversight and quality assurance ... Dr. Vitiello among our team of experienced reproductive endocrinologists,” ... Joseph A. Hill, M.D. “Her expertise and compassionate, individualized ...
(Date:5/28/2015)... 28, 2015 Global futurist and ... to ask his audiences if they are ready ... robotics, solar cells, fuel cells, rapid health care ... battery storage technology, driverless cars, artificial intelligence masquerading ... inexpensive online education. , While the majority ...
(Date:5/28/2015)... 28, 2015 In two different ... Sherley, M.D., Ph.D., will present the company’s unique approach ... a conference talk, he will describe Asymmetrex ’s ... with computer simulation to produce the first-ever technology for ... quality over time in culture. When leading an ...
(Date:5/27/2015)... , May 27, 2015 RXi ... company focused on discovering and developing innovative therapies ... today announced that it has commenced a public offering ... purchase shares of its common stock and overallotment ... stock. The shares of common stock, warrants and ...
Breaking Biology Technology:Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2Futurist Jack Uldrich to Deliver 4 Keynote Addresses in June 2Asymmetrex Will Discuss the Importance of Adult Tissue Stem Cell Time with 3D Tissue Engineers at the 14th Annual World Preclinical Congress in Boston in June 2Asymmetrex Will Discuss the Importance of Adult Tissue Stem Cell Time with 3D Tissue Engineers at the 14th Annual World Preclinical Congress in Boston in June 3RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3
... China, April 8 Sinobiopharma Pharmaceutical Group (OTC ... appointment of Ms. Yan Tan as Director of ... Ltd., Netherlands. She served as a China-based Unit ... to Schering-Plough. Prior to Organon, Ms. Tan held ...
... the simplicity of protein precipitation with the ... of phospholipids and proteins from biological samples ... Supelco, a division of Sigma-Aldrich (Nasdaq: ... supplier of chromatography products for analysis and ...
... April 8 ImQuest Life Sciences presented their ... their novel small molecule piperazine compound for the ... Therapeutics meeting held in Whistler, British Columbia. The ... lead microtubule inhibitor, IQP-0304. The piperazines demonstrate potent ...
Cached Biology Technology:Sinobiopharma, Inc. Appoints New Director of Marketing 2HybridSPE(TM)-Precipitation Technology Wins SelectScience.net 2009 Scientists' Choice Award for Best New Separations Product in 2008 2HybridSPE(TM)-Precipitation Technology Wins SelectScience.net 2009 Scientists' Choice Award for Best New Separations Product in 2008 3ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program 2
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a ... established helmet producer, announced today that they will expand ... the world,s first bio-sensing cycling helmet and the first ... in two new colors in order to give cyclists ... product. In addition, LifeBEAM and Lazer announced their plan ...
(Date:4/27/2015)... 2015 Profile Solutions, Inc. (OTC: PSIQ), a ... is pleased to announce that Dr Gerry Bedore ... member of its scientific advisory board. ... thought leader in technology-enhanced learning models. He was a ... published studies and books focused on online student success ...
(Date:4/17/2015)... Increasing adoption in ... to drive biometric systems market in ... According to a recently released TechSci Research ... biometric systems market in Saudi Arabia ... CAGR of over 22% through 2020. The market ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... of the Canadian Journal of Forest Research presents ... one of the first landscape-scale experiments on how ... The Blacks Mountain Interdisciplinary Research team includes U.S. ... U.C. Riverside, University of Georgia and Wildlife Conservation ...
... ago, bird beaks are exquisitely adapted to the birds, feeding ... explained exactly how some shorebirds use their long, thin beaks ... The phalarope, commonly found in western North America, takes advantage ... propel bits of food from the tip of its long ...
... Mass.--Having found that whether bacteria stick to surfaces depends ... have created ultrathin films made of polymers that could ... control microbe accumulation. The inexpensive, easy-to-produce films could ... care industry by helping to reduce the spread of ...
Cached Biology News:Pioneering landscape-scale research releases first findings 2MIT solves gravity-defying bird beak mystery 2MIT solves gravity-defying bird beak mystery 3MIT crafts bacteria-resistant films 2MIT crafts bacteria-resistant films 3